What the landmark SELECT trial, the FDA’s 2024 approval, and the latest cardiology evidence reveal about GLP-1 medications and your heart.
| KEY TAKEAWAYS• The SELECT trial showed semaglutide cuts heart attack, stroke, and CV death risk by 20% in adults with heart disease and excess weight.• The FDA approved Wegovy in March 2024 as the first weight-loss medication cleared for heart protection.• Benefits extend beyond weight loss to inflammation, blood pressure, and arrhythmia risk. |
Heart disease is the leading cause of death in India, and the evidence on GLP-1 medications has changed how cardiologists think about prevention. Here is what the latest trials show about GLP-1 cardiovascular benefits, who they help, and what to watch for.
How GLP-1 Cardiovascular Benefits Work Beyond Weight Loss
GLP-1 receptor agonists were first developed for type 2 diabetes, but research now shows they protect the heart through several pathways at once. These medications affect inflammation, blood pressure, cholesterol, and blood vessel function in ways that may not depend on weight loss alone.
In the SELECT trial, semaglutide reduced high-sensitivity C-reactive protein (a key inflammation marker) by approximately 39%, lowered systolic blood pressure by about 3.8 mmHg, and reduced LDL cholesterol by around 5%. These changes appeared early, often within the first few months of treatment.
GLP-1 receptors are present not only in the pancreas, but also in the heart, blood vessels, kidneys, and central nervous system.
Through this wide distribution, GLP-1 agonists may improve endothelial function, reduce oxidative stress, slow atherosclerosis progression, and modulate sympathetic activity.
A 2025 prespecified analysis published in The Lancet found that the cardiovascular benefit of semaglutide appeared largely independent of weight loss.
This suggests GLP-1 medications work through multiple mechanisms, not weight reduction alone.
Practical takeaway: Cardiovascular protection from GLP-1 therapy may begin before significant weight is lost, and likely involves direct effects on the cardiovascular system.
| Mechanism | Effect on the Heart and Vessels |
|---|---|
| Reduction in systemic inflammation | Slower atherosclerotic plaque progression, lower hsCRP |
| Improved endothelial function | Better vasodilation, reduced arterial stiffness |
| Modest blood pressure reduction | Lower workload on the heart |
| Improved lipid profile | Reduced LDL cholesterol and triglycerides |
| Weight and visceral fat loss | Reduced metabolic and mechanical burden on the heart |
| Improved insulin sensitivity | Lower long-term diabetes and cardiovascular risk |
The SELECT Trial: Landmark Evidence for GLP-1 Cardiovascular Benefits
The SELECT trial is the largest cardiovascular outcomes study ever conducted in people with obesity. It enrolled 17,604 adults across 41 countries who had established cardiovascular disease and a BMI of 27 or higher, but no diabetes.
Participants received either weekly semaglutide 2.4 mg (Wegovy) or a placebo, alongside standard heart-disease care. After an average follow-up of about 40 months, the results changed clinical practice.
The primary endpoint, a composite of cardiovascular death, non-fatal heart attack, and non-fatal stroke, occurred in 6.5% of the semaglutide group compared with 8.0% of the placebo group. That represents a 20% relative risk reduction (HR 0.80, 95% CI 0.72 to 0.90, P<0.001).
Cardiovascular death dropped by 15% and all-cause death dropped by 19%. The benefits appeared regardless of age, sex, race, BMI, or kidney function.
Based on these results, the FDA approved Wegovy in March 2024 for cardiovascular risk reduction in adults with established heart disease and excess weight.
| SELECT Trial Result | Semaglutide 2.4 mg | Placebo |
|---|---|---|
| Participants | 8,803 | 8,801 |
| Average follow-up | ~40 months | ~40 months |
| Primary endpoint (CV death, MI, stroke) | 6.5% | 8.0% |
| Relative risk reduction (MACE) | 20% (HR 0.80, 95% CI 0.72 to 0.90) | reference |
| CV death reduction | 15% | reference |
| All-cause death reduction | 19% | reference |
| Mean weight loss at 4 years | 10.2% | 1.5% |
Read the full primary publication in the New England Journal of Medicine and the FDA approval announcement.
How GLP-1 Reduces Heart Attack and Stroke Risk
Heart attack and stroke account for the largest share of cardiovascular deaths globally, including in India. The SELECT trial broke down the 20% MACE reduction into its components, and the data on heart attack prevention is particularly clear.
Non-fatal myocardial infarction was reduced by 28% in the semaglutide group (HR 0.72, 95% CI 0.61 to 0.85). Non-fatal stroke showed a smaller numerical reduction that did not reach statistical significance on its own, although the combined endpoint was strongly positive.
A 2025 follow-up analysis presented at major cardiology conferences found that the reduction in heart events emerged within the first 3 months of treatment, possibly as early as 3 weeks.
This early benefit may be linked to the rapid drop in inflammation rather than the slower decline in body weight.
Importantly, the SELECT trial enrolled only patients with established heart disease (prior heart attack, prior stroke, or symptomatic peripheral artery disease).
The cardiovascular benefit demonstrated by semaglutide is, therefore, currently best supported in this secondary prevention setting.
For people with type 2 diabetes, multiple earlier outcome trials including SUSTAIN 6 and LEADER had already shown that GLP-1 medications can reduce major cardiovascular events. Cardiac-risk patients with type 1 diabetes are a separate, less-studied group; for what the current evidence on GLP-1 in type 1 diabetes actually shows on cardiac and metabolic endpoints, see our dedicated review.
The recent SOUL trial, published in 2025, found that oral semaglutide reduced MACE by 14% in adults with type 2 diabetes and established cardiovascular disease.
| WHAT THIS MEANSFor a patient with prior heart attack or peripheral artery disease and excess weight, semaglutide added to standard care may meaningfully reduce the chance of another major cardiovascular event. |
GLP-1 and Heart Failure: Promising Evidence in HFpEF
Heart failure with preserved ejection fraction (HFpEF) is a common form of heart failure with limited treatment options. Recent GLP-1 trials suggest these medications may help.
The STEP-HFpEF trial enrolled 529 patients with obesity and HFpEF (without diabetes). After 52 weeks, semaglutide produced a 7.8-point greater improvement in heart failure symptoms (KCCQ-CSS score), a 21.5-metre greater improvement in 6-minute walk distance, and a roughly 39% reduction in C-reactive protein versus placebo.
The SUMMIT trial tested tirzepatide, a dual GLP-1/GIP receptor agonist, in patients with HFpEF and obesity. It produced similar improvements in symptoms and exercise capacity, along with a near-40% reduction in cardiovascular death or worsening heart failure events.
A real-world analysis of US claims data, published in 2025, found that semaglutide and tirzepatide were each associated with a 40% to 58% lower risk of heart failure hospitalisation or death compared with sitagliptin in patients with HFpEF.
A prespecified SELECT analysis published in The Lancet showed that semaglutide reduced cardiovascular events even in patients with pre-existing heart failure, regardless of whether the heart failure was preserved or reduced ejection fraction.
For patients with heart failure with reduced ejection fraction (HFrEF), the evidence is less clear. Some earlier trials with liraglutide raised concerns about adverse outcomes in this population. Therapy choice should be individualised by a cardiologist.
| WHAT THIS MEANSFor people with obesity and HFpEF, GLP-1 therapy may improve quality of life, exercise capacity, and possibly long-term outcomes. The evidence in HFrEF remains uncertain. |
GLP-1 and Heart Arrhythmia: What the Data Show on Atrial Fibrillation
A common concern is whether GLP-1 medications cause or worsen heart arrhythmia. The data are reassuring, particularly for atrial fibrillation (AF).
A 2026 meta-analysis published in Metabolism reviewed 24 randomised controlled trials with 40,694 participants. It found that GLP-1 receptor agonists were associated with an 18% relative reduction in AF risk in people with overweight or obesity (RR 0.82, 95% CI 0.70 to 0.96).
A separate 2024 meta-analysis in the European Journal of Clinical Investigation focused on semaglutide and showed a 42% lower incidence of AF compared with placebo, based on 12,651 patients across 10 trials.
For ventricular arrhythmias and sudden cardiac death, large meta-analyses have found no increased risk. In the LEADER and SUSTAIN-6 trials, small heart rate increases occurred alongside fewer major cardiac events, suggesting the cardioprotective benefit clearly outweighs any modest autonomic change.
For patients with HFpEF, a 2025 meta-analysis of randomised trials (including SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF-DM) found that GLP-1 therapy was associated with a 46% lower risk of incident AF compared with placebo (RR 0.54, 95% CI 0.36 to 0.81).
| WHAT THIS MEANSGLP-1 medications appear to reduce AF risk overall and do not increase the risk of dangerous ventricular arrhythmias. Patients with existing arrhythmias should be reviewed individually by their cardiologist. |
Heart Rate, Palpitations, and Blood Pressure on GLP-1 Therapy
GLP-1 medications produce a small, well-documented increase in resting heart rate. The size of the effect depends on the formulation.
A meta-analysis of phase 3 trials reported heart rate increases in the range of 1 to 4 beats per minute for the once-weekly long-acting agents (such as exenatide LAR, dulaglutide, and liraglutide).
For once-daily liraglutide, ambulatory monitoring has shown a slightly higher mean increase. Patients sometimes notice this as mild palpitations during the first few weeks of therapy.
The mechanism appears to involve effects of GLP-1 receptors in the autonomic nervous system. These can slightly raise sympathetic tone or reduce vagal (parasympathetic) tone. Despite this, large outcome trials consistently show net cardiovascular benefit, not harm.
Blood pressure typically moves the other way. SELECT showed a mean systolic blood pressure reduction of about 3.8 mmHg with semaglutide.
A 2025 review in PMC summarised that GLP-1 medications lower both systolic and diastolic pressure through several mechanisms, including weight loss, improved endothelial function, reduced arterial stiffness, and modulation of sympathetic activity.
| Cardiovascular Marker | Typical Change on GLP-1 Therapy |
|---|---|
| Resting heart rate | Increase of 1 to 4 bpm (long-acting agents) |
| Systolic blood pressure | Reduction of 3 to 5 mmHg on average |
| Diastolic blood pressure | Modest reduction |
| Body weight | Sustained reduction of 5% to 15% over 1 to 4 years |
| hsCRP (inflammation) | Reduction of 30% to 40% |
| LDL cholesterol | Reduction of 3% to 5% |
| WHAT THIS MEANSMild palpitations or a slightly faster pulse may occur in the first weeks of GLP-1 therapy. These changes are usually not clinically significant, but persistent or symptomatic palpitations should always be reviewed with a cardiologist or treating doctor. |
GLP-1 and Cardio Exercise: Combining Therapy with Movement
Cardio exercise remains a foundational part of cardiovascular protection, and GLP-1 medications are not a replacement. The SELECT trial protocol included counselling on physical activity and healthy eating for both treatment groups.
Combining cardio exercise with GLP-1 therapy may offer additive benefits. Evidence from STEP-HFpEF and SUMMIT showed that GLP-1 medications improved 6-minute walk distance and exercise tolerance, suggesting they may make movement more comfortable for people with existing fitness limitations.
For people on GLP-1 therapy, current cardiology guidance generally recommends:
- At least 150 minutes per week of moderate-intensity aerobic activity (such as brisk walking, cycling, or swimming).
- 2 sessions per week of resistance training to preserve muscle mass during weight loss.
- Gradual progression, especially for those with established heart disease.
A 2024 review in Cardiac Failure Review noted that combining exercise training with GLP-1 medications may help reduce sarcopenia and frailty risk during weight loss. Importantly, exercise training may also help attenuate gastrointestinal side effects of GLP-1 therapy.
The 2025 ACC Expert Consensus Statement on Medical Weight Management specifically encourages clinicians to pair GLP-1 medications with structured lifestyle interventions, rather than using them as a standalone strategy.
| WHAT THIS MEANSGLP-1 therapy works best as a partner to lifestyle changes, not a substitute. Always discuss any new exercise program with a doctor, particularly for people with established heart disease. |
Bottom Line
GLP-1 cardiovascular benefits are now backed by some of the strongest evidence in modern cardiology. The SELECT trial established that semaglutide reduces heart attack, stroke, and cardiovascular death by about 20% in people with established heart disease and excess weight, even without diabetes.
For patients in India, where cardiovascular disease accounts for roughly one in four deaths, talking with a cardiologist about whether GLP-1 therapy fits an overall prevention plan may be a meaningful next step.
Frequently Asked Questions
Q1. Does GLP-1 make your heart beat faster?
Ans. GLP-1 medications can slightly raise resting heart rate, typically by 1 to 4 beats per minute for once-weekly agents. This effect is generally modest and well tolerated. Persistent or symptomatic palpitations should be discussed with a doctor.
Q2. Do GLP-1 improve heart health?
Ans. Yes. Large trials including SELECT show GLP-1 medications can lower the risk of heart attack, stroke, and cardiovascular death in high-risk patients. They may also reduce inflammation and blood pressure, although individual benefit is best confirmed by an evaluation with a cardiologist.
Q3. What do cardiologists think of GLP-1?
Ans. Most cardiologists now view GLP-1 medications as an important tool for high-risk patients with obesity or diabetes and heart disease. The 2025 American College of Cardiology Expert Consensus Statement identifies semaglutide and tirzepatide as preferred medications among approved options.
Q4. Can GLP-1 cause heart failure?
Ans. Current evidence does not show that GLP-1 medications cause heart failure in most patients. Trials such as STEP-HFpEF and the SELECT prespecified heart failure analysis suggest they may improve outcomes in heart failure with preserved ejection fraction. Patients with existing heart failure should always discuss therapy choice with a cardiologist.
Q5. Does GLP-1 reduce blood pressure?
Ans. Yes. GLP-1 medications can produce modest reductions in systolic and diastolic blood pressure. In the SELECT trial, semaglutide reduced systolic blood pressure by an average of about 3.8 mmHg. They are not a substitute for dedicated blood pressure medications when those are clinically needed.
Q6. What are the cardiovascular benefits of GLP-1 medications?
Ans. GLP-1 cardiovascular benefits include reductions in heart attack risk, stroke risk, cardiovascular death, blood pressure, inflammation, and possibly atrial fibrillation incidence. Most direct outcome data come from semaglutide. Individual benefit depends on baseline risk and should be assessed by a doctor.
Q7. Can GLP-1 reduce risk of heart attack and stroke?
Ans. Yes. The SELECT trial showed semaglutide reduced the combined risk of cardiovascular death, non-fatal heart attack, and non-fatal stroke by 20% in adults with established heart disease and excess weight. The benefit was strongest for non-fatal heart attack reduction.
Q8. Is Wegovy or Ozempic approved for heart disease prevention?
Ans. Wegovy (semaglutide 2.4 mg) was approved by the US FDA in March 2024 to reduce the risk of cardiovascular death, heart attack, and stroke in adults with heart disease and excess weight. Ozempic (semaglutide 1.0 mg) is approved to reduce major cardiovascular events in adults with type 2 diabetes and established heart disease.
Q9. Which GLP-1 is FDA approved for cardiovascular benefit?
Ans. Several GLP-1 medications carry FDA approval for cardiovascular risk reduction. Wegovy (semaglutide) is approved for adults with obesity and heart disease. Ozempic, Trulicity (dulaglutide), Victoza (liraglutide), and oral Rybelsus (semaglutide tablets, label expanded in October 2025) are approved in patients with type 2 diabetes and cardiovascular risk.
Sources
1. Lincoff AM, et al. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes. New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2307563
2. US Food and Drug Administration. FDA Approves First Treatment to Reduce Risk of Serious Heart Problems Specifically in Adults with Obesity or Overweight. March 8, 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or
3. Ryan DH, et al. Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial. Nature Medicine, 2024. https://www.nature.com/articles/s41591-024-02996-7
4. Deanfield J, et al. Semaglutide and cardiovascular outcomes in patients with obesity and prevalent heart failure: a prespecified analysis of the SELECT trial. The Lancet, 2024. https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01498-3/fulltext
5. Kosiborod MN, et al. Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity (STEP-HFpEF). New England Journal of Medicine, 2023. https://www.nejm.org/doi/full/10.1056/NEJMoa2306963
6. McGuire DK, et al. Oral Semaglutide and Cardiovascular Outcomes in High-Risk Type 2 Diabetes (SOUL Trial). New England Journal of Medicine, 2025. https://www.nejm.org/doi/full/10.1056/NEJMoa2501006
7. Karakasis P, et al. Effect of GLP-1 receptor agonists and co-agonists on atrial fibrillation risk in overweight or obesity: systematic review and meta-analysis. Metabolism, 2026. https://pubmed.ncbi.nlm.nih.gov/41349790/
8. Saglietto A, et al. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis. European Journal of Clinical Investigation, 2024. https://onlinelibrary.wiley.com/doi/10.1111/eci.14292
9. Marso SP, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes (LEADER). New England Journal of Medicine, 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1603827
10. Marso SP, et al. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes (SUSTAIN-6). New England Journal of Medicine, 2016. https://www.nejm.org/doi/full/10.1056/NEJMoa1607141
11. American College of Cardiology. 2025 Concise Clinical Guidance: An ACC Expert Consensus Statement on Medical Weight Management for Optimization of Cardiovascular Health. JACC, 2025. https://www.jacc.org/doi/10.1016/j.jacc.2025.05.024
12. Russo G, et al. The Beneficial Effects of Glucagon-Like Peptide-1 Agonists on Blood Pressure: A Comprehensive Review. PMC, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12780994/
13. Yan H, et al. U.S. Eligibility and Preventable Cardiovascular, Diabetes, and Kidney Outcomes From Semaglutide in the SELECT Trial. JACC: Advances, 2025. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12277595/
14. Packer M, et al. Tirzepatide for Heart Failure with Preserved Ejection Fraction and Obesity (SUMMIT). New England Journal of Medicine, 2024. https://www.nejm.org/doi/full/10.1056/NEJMoa2410027
15. Madonna R, et al. Effects of Glucagon-like Peptide-1 Receptor Agonists on Cardiac Function, Exercise Capacity and Quality of Life. Cardiac Failure Review, 2024. https://pubmed.ncbi.nlm.nih.gov/39309521/
16. Anjana RM, et al. High prevalence of metabolic obesity in India: The ICMR-INDIAB national study. Indian Journal of Medical Research, 2025. https://pmc.ncbi.nlm.nih.gov/articles/PMC12550443/
